← Back to Screener
Ionis Pharmaceuticals, Inc. Common Stock (IONS)
Price$74.87
Favorite Metrics
Price vs S&P 500 (26W)-0.83%
Price vs S&P 500 (4W)-2.38%
Market Capitalization$12.37B
All Metrics
Book Value / Share (Quarterly)$2.99
P/TBV (Annual)5.79x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)17.12%
Cash Flow / Share (Quarterly)$-1.96
Price vs S&P 500 (YTD)-9.29%
Gross Margin (TTM)98.27%
Net Profit Margin (TTM)-40.40%
EPS (TTM)$-2.47
10-Day Avg Trading Volume1.44M
EPS Excl Extra (TTM)$-2.47
Revenue Growth (5Y)5.29%
EPS (Annual)$-2.38
ROI (Annual)-13.53%
Gross Margin (Annual)98.31%
Net Profit Margin (5Y Avg)-40.14%
Cash / Share (Quarterly)$16.40
Revenue Growth QoQ (YoY)-10.43%
ROA (Last FY)-10.82%
Revenue Growth TTM (YoY)33.82%
EBITD / Share (TTM)$-2.78
ROE (5Y Avg)-60.13%
Operating Margin (TTM)-40.43%
Cash Flow / Share (Annual)$-1.96
P/B Ratio25.29x
P/B Ratio (Quarterly)26.20x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)15.17x
Net Interest Coverage (TTM)-4.22x
ROA (TTM)-12.35%
EV / EBITDA (TTM)557.45x
EPS Incl Extra (Annual)$-2.38
Current Ratio (Annual)3.83x
Quick Ratio (Quarterly)3.81x
3-Month Avg Trading Volume2.11M
52-Week Price Return163.63%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$3.98
P/S Ratio (Annual)13.11x
Asset Turnover (Annual)0.27x
52-Week High$86.74
Operating Margin (5Y Avg)-45.13%
EPS Excl Extra (Annual)$-2.38
CapEx CAGR (5Y)7.95%
Tangible BV CAGR (5Y)56.47%
26-Week Price Return6.06%
Quick Ratio (Annual)3.81x
13-Week Price Return-3.03%
Total Debt / Equity (Annual)4.77x
Current Ratio (Quarterly)3.83x
Enterprise Value$14,326.41
Revenue / Share Growth (5Y)2.46%
Asset Turnover (TTM)0.31x
Book Value / Share Growth (5Y)-10.77%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.41x
Pretax Margin (Annual)-40.22%
Cash / Share (Annual)$16.40
3-Month Return Std Dev31.22%
Gross Margin (5Y Avg)98.36%
Net Income / Employee (TTM)$-0
ROE (Last FY)-77.98%
Net Interest Coverage (Annual)-13.03x
EPS Basic Excl Extra (Annual)$-2.38
P/FCF (TTM)88.96x
Receivables Turnover (TTM)11.93x
Total Debt / Equity (Quarterly)4.77x
EPS Incl Extra (TTM)$-2.47
Receivables Turnover (Annual)11.93x
ROI (TTM)-15.41%
P/S Ratio (TTM)13.10x
Pretax Margin (5Y Avg)-39.07%
Revenue / Share (Annual)$5.90
Tangible BV / Share (Annual)$5.26
Price vs S&P 500 (52W)128.99%
Year-to-Date Return-5.36%
5-Day Price Return-2.46%
EPS Normalized (Annual)$-2.38
ROA (5Y Avg)-9.98%
Net Profit Margin (Annual)-40.41%
Month-to-Date Return-0.29%
Cash Flow / Share (TTM)$-2.77
EBITD / Share (Annual)$-2.88
Operating Margin (Annual)-40.45%
LT Debt / Equity (Annual)3.88x
ROI (5Y Avg)-13.25%
LT Debt / Equity (Quarterly)3.88x
EPS Basic Excl Extra (TTM)$-2.47
P/TBV (Quarterly)11.12x
P/B Ratio (Annual)26.20x
Inventory Turnover (TTM)1.41x
Pretax Margin (TTM)-40.21%
Book Value / Share (Annual)$2.99
Price vs S&P 500 (13W)-5.41%
Beta0.38x
P/FCF (Annual)657.87x
Revenue / Share (TTM)$5.81
ROE (TTM)-68.89%
52-Week Low$27.90
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.07
4.07
4.07
4.07
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IONSIonis Pharmaceuticals, Inc. Common Stock | 13.10x | 33.82% | 98.27% | — | $74.87 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.71 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Ionis Pharmaceuticals is a leader in antisense technology with a diverse clinical pipeline targeting cardiovascular, metabolic, neurological, and rare diseases. The company has established multiple marketed drugs through partnerships, including Spinraza (spinal muscular atrophy), Qalsody (ALS), and Tegsedi (ATTR amyloidosis), while achieving its first independent launches in 2025 with Tryngolza and Dawnzera. Ionis combines partnership-driven revenue streams with growing direct commercialization capabilities.